Annual global cancer incidence rates are expected to rise by nearly 60% in the next 20 years, prompting drug developers to get creative in their fight against cancer.
News & Analysis: Threshold Pharmaceuticals
All three of these small-cap biotech stocks could return 200% (or more) for their shareholders if Wall Street's price targets are accurate.
Can your stomach handle the risk associated with these potentially high-flying biotech growth stocks?
Wall Street has cast these three biotech stocks to the proverbial scrap heap over the past five years, but a big rebound may soon be in order.
Shares of the clinical-stage biopharma Threshold Pharmaceuticals shot higher today. Here's why.
Don't let their share price fool you. These five biotech stocks have the potential to double your money many times over if their product pipelines meet expectations.
We know chemotherapy kills cancer cells, but it's also an indiscriminate killer of healthy cells. According to a new study released this past week, an entirely new treatment pathway could eliminate a significant portion of healthy cell death.
Pancreatic cancer is the fourth-leading cause of cancer-related death, but researchers may have moved one step closer to discovering a cure this past week.
Do Westport Innovations, Threshold Pharmaceuticals, and and Rowan Cos. deserve a second chance? You be the judge!
Pancreatic cancer has the lowest five-year survival rate and is the most prevalent in these five states. Here are the existing and developing therapies you need to have your eyes on.